These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 173867)

  • 1. In vitro evaluation of cell-mediated immunity to Epstein-Barr herpesvirus by cell migration inhibition tests.
    Lai PK; Alpers MP; Mackay Scollay EM
    J Natl Cancer Inst; 1975 Dec; 55(6):1319-22. PubMed ID: 173867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr herpesvirus infection: inhibition by immunologically induced mediators with interferon-like properties.
    Lai PK; Alpers MP; MacKay-Scollay EM
    Int J Cancer; 1977 Jul; 20(1):21-9. PubMed ID: 198380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of an Epstein-Barr virus-associated membrane antigen in Epstein-Barr virus-transformed nonproducer cells by leukocyte migration inhibition and blocking antibody.
    Szigeti R; Sulitzeanu D; Henle G; Henle W; Klein G
    Proc Natl Acad Sci U S A; 1984 Jul; 81(13):4178-82. PubMed ID: 6330746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocyte migration inhibition detects cross-reacting antigens between cells transformed by Epstein-Barr virus (EBV) and EBV-like simian viruses.
    Szigeti R; Rabin H; Timar L; Klein G
    Intervirology; 1986; 26(3):121-8. PubMed ID: 3034820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocyte migration inhibition studies with Epstein-Barr virus (EBV) determined nuclear antigen (EBNA) in relation to the EBV-carrier status of the donor.
    Szigeti R; Luka J; Klein G
    Cell Immunol; 1981 Mar; 58(2):269-76. PubMed ID: 6260386
    [No Abstract]   [Full Text] [Related]  

  • 6. Cell mediated immunity during infectious mononucleosis to Epstein-Barr virus associated antigens.
    Periman P; Levine PH; Ablashi DV; Royston I
    Int J Cancer; 1977 Oct; 20(4):506-11. PubMed ID: 199544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of cell-mediated immunity to Epstein-Barr herpesvirus in infectious mononucleosis as shown by leukocyte migration inhibition.
    Lai PK; Alpers MP; MacKay-Scollay EM
    Infect Immun; 1977 Jul; 17(1):28-35. PubMed ID: 195902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-mediated immunity to Epstein-Barr virus and a blocking factor in patients with infectious mononucleosis.
    Lai PK; Mackay-Scollay EM; Fimmel PJ; Alpers MP; Keast D
    Nature; 1974 Dec; 252(5484):608-10. PubMed ID: 4372559
    [No Abstract]   [Full Text] [Related]  

  • 9. Epstein-Barr virus-specific leukocyte migration inhibition reaction with tumor biopsy extracts: correlation with the presence of viral DNA.
    Szigeti R; Saemundsen AK; Synnerholm AC; Henle G; Henle W; Klein G
    Cancer Res; 1983 May; 43(5):2273-6. PubMed ID: 6299543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum modulation of in vitro cellular immune reactivity to Epstein-Barr virus-associated antigen.
    Holt PG; Fimmel PJ; Roberts LM; Keast D
    Med Microbiol Immunol; 1976 Dec; 162(3-4):209-16. PubMed ID: 187919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of migration inhibitory factor (MIF) by human leukocytes following exposure to Epstein-Barr virus.
    Wilson GL; Young BG
    Cell Immunol; 1978 Jun; 38(1):147-56. PubMed ID: 208782
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of adenine arabinoside on Epstein-Barr virus in vitro.
    Coker-Vann M; Dolin R
    J Infect Dis; 1977 Mar; 135(3):447-53. PubMed ID: 191542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
    Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
    Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.
    Sairenji T; Reisert PS; Spiro RC; Connolly T; Humphreys RE
    J Exp Med; 1985 May; 161(5):1097-111. PubMed ID: 2580934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cellular immunity to Epstein-Barr virus in normal human subjects.
    Fimmel PJ; Lai PK; Keast D; Alpers MP; Mackay-Scollay EM
    Int J Cancer; 1974 May; 13(5):599-605. PubMed ID: 4367339
    [No Abstract]   [Full Text] [Related]  

  • 16. Control of interferon, migration inhibition factor, and expression of virus capsid antigens in Burkitt's lymphoma-derived cell lines: role of L-arginine.
    Archer DL; Young BG
    Infect Immun; 1974 Apr; 9(4):684-9. PubMed ID: 4362772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte migration inhibition with Epstein-Barr virus negative and positive cell extracts.
    Szigeti R; Timár L; Révész T
    Allergy; 1980 Mar; 35(2):97-103. PubMed ID: 6155797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
    Fresen KO; zur Hausen H
    Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel surface antigen on lymphoid cells transformed by Epstein-Barr virus.
    Hinuma Y; Sakamoto K
    IARC Sci Publ (1971); 1978; (24 Pt 1):249-51. PubMed ID: 87368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocyte migration inhibition demonstrates a human T-cell response to a membrane protein expressed in latent Epstein-Barr virus infection.
    Sulitzeanu D; Szigeti R; Klein G; Hennessy K; Kieff E
    J Virol; 1986 Apr; 58(1):230-2. PubMed ID: 3005653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.